Identifying mAbs targeting unique epitopes is therefore highly desirable from a discovery perspective because they may offer mechanistically differentiated MOA’s and highly valuable IP opportunities. Epitope screening only a subset of a panel due to throughput limitations restricts epitope diversity, thereby negatively impacting the success of therapeutic drug discovery.